Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating restated by investment analysts at Cantor Fitzgerald in a report issued on Friday, May 12th. They presently have a $21.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 346.81% from the stock’s current price.
The analysts wrote, “At the ASGCT meeting in Washington D.C., Abeona announced initial 30-day data in two patients treated with a high dose of ABO-102.””
ABEO has been the subject of several other reports. Rodman & Renshaw reaffirmed a “buy” rating and issued a $20.00 target price (up from $17.00) on shares of Abeona Therapeutics in a report on Tuesday, February 7th. Zacks Investment Research upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research note on Tuesday, January 31st. Jefferies Group LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Abeona Therapeutics in a research note on Friday, February 17th. Maxim Group set a $14.00 target price on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 18th. Finally, HC Wainwright set a $20.00 target price on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, February 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Abeona Therapeutics has an average rating of “Buy” and a consensus price target of $15.18.
Abeona Therapeutics (NASDAQ ABEO) traded down 1.05% during trading on Friday, reaching $4.70. The company’s stock had a trading volume of 191,091 shares. The stock’s 50 day moving average is $5.54 and its 200-day moving average is $5.26. The firm’s market cap is $189.20 million. Abeona Therapeutics has a 52 week low of $2.31 and a 52 week high of $9.44.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, May 18th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.28 million. Abeona Therapeutics had a negative return on equity of 26.99% and a negative net margin of 2,568.57%. On average, equities research analysts forecast that Abeona Therapeutics will post ($0.58) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. raised its stake in Abeona Therapeutics by 869.7% in the first quarter. Goldman Sachs Group Inc. now owns 116,000 shares of the biopharmaceutical company’s stock worth $580,000 after buying an additional 104,038 shares in the last quarter. Family Management Corp purchased a new stake in Abeona Therapeutics during the first quarter worth $120,000. Highbridge Capital Management LLC raised its stake in Abeona Therapeutics by 23.5% in the first quarter. Highbridge Capital Management LLC now owns 681,611 shares of the biopharmaceutical company’s stock worth $3,408,000 after buying an additional 129,811 shares in the last quarter. Morgan Stanley raised its stake in Abeona Therapeutics by 2,555.0% in the first quarter. Morgan Stanley now owns 104,632 shares of the biopharmaceutical company’s stock worth $523,000 after buying an additional 100,691 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Abeona Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 4,588 shares in the last quarter. 35.84% of the stock is currently owned by hedge funds and other institutional investors.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
What are top analysts saying about Abeona Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abeona Therapeutics Inc. and related companies.